(Q38442184)

3 September 2017

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen (English)

1 reference

3 September 2017

1 reference

5

Albert Hofman

1 reference

3 September 2017

Rikje Ruiter

1

1 reference

3 September 2017

Monique J Bijl

2

1 reference

3 September 2017

Ron H N van Schaik

3

1 reference

3 September 2017

Els M J J Berns

4

1 reference

3 September 2017

Jan-Willem W Coebergh

6

1 reference

3 September 2017

Charlotte van Noord

7

1 reference

3 September 2017

Loes E Visser

8

1 reference

3 September 2017

Bruno H Ch Stricker

9

1 reference

3 September 2017

1 October 2010

1 reference

3 September 2017

1 reference

3 September 2017

11

1 reference

3 September 2017

1367-1375

1 reference

3 September 2017

10

1 reference

Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

3 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Genotype-guided tamoxifen therapy: time to pause for reflection?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The Rotterdam Study: 2010 objectives and design update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The Rotterdam Study: objectives and design update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Determinants of disease and disability in the elderly: The Rotterdam elderly study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

CYP2C19*17 is associated with decreased breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.112

21 January 2018

Identifiers

DOI

10.2217/PGS.10.112

1 reference

3 September 2017

1 reference